Farallon Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-6,656,823
| Closed | -$770M | – | 187 |
|
|
2023
Q3 | $770M | Sell |
6,656,823
-265,000
| -4% | -$30.7M | 3.6% | 3 |
|
|
2023
Q2 | $712M | Buy |
6,921,823
+1,502,000
| +28% | +$154M | 3.57% | 3 |
|
|
2023
Q1 | $592M | Buy |
5,419,823
+1,724,900
| +47% | +$188M | 3.23% | 4 |
|
|
2022
Q4 | $420M | Buy |
3,694,923
+1,914,700
| +108% | +$218M | 2.48% | 7 |
|
|
2022
Q3 | $110M | Buy |
1,780,223
+687,063
| +63% | +$42.5M | 0.61% | 48 |
|
|
2022
Q2 | $0 | Buy |
+1,093,160
| New | – | ﹤0.01% | 342 |
|
|
2022
Q1 | – | Sell |
-1,396,217
| Closed | -$150M | – | 35 |
|
|
2021
Q4 | $150M | Buy |
1,396,217
+224,043
| +19% | +$24.1M | 0.75% | 35 |
|
|
2021
Q3 | $128M | Buy |
1,172,174
+672,174
| +134% | +$73.6M | 0.6% | 46 |
|
|
2021
Q2 | $46.8M | Buy |
+500,000
| New | +$46.8M | 0.19% | 72 |
|
|
2020
Q4 | – | Sell |
-150,000
| Closed | -$11.7M | – | 165 |
|
|
2020
Q3 | $11.7M | Buy |
+150,000
| New | +$11.7M | 0.08% | 97 |
|
|
2017
Q3 | – | Sell |
-745,000
| Closed | -$8.84M | – | 98 |
|
|
2017
Q2 | $8.84M | Sell |
745,000
-1,650,000
| -69% | -$19.6M | 0.09% | 68 |
|
|
2017
Q1 | $35.4M | Buy |
2,395,000
+1,785,000
| +293% | +$26.4M | 0.39% | 42 |
|
|
2016
Q4 | $9.87M | Buy |
+610,000
| New | +$9.87M | 0.11% | 54 |
|
|
2014
Q1 | – | Sell |
-829,420
| Closed | -$6.32M | – | 106 |
|
|
2013
Q4 | $6.32M | Sell |
829,420
-1,393,651
| -63% | -$10.6M | 0.13% | 61 |
|
|
2013
Q3 | $7.45M | Hold |
2,223,071
| – | – | 0.15% | 57 |
|
|
2013
Q2 | $5.47M | Buy |
+2,223,071
| New | +$5.47M | 0.1% | 63 |
|